Accelerate Diagnostics Scheduled Call to Review 2024 Third Quarter Results - StockTitan

AXDX Stock  USD 1.57  0.13  7.65%   
Slightly above 62% of Accelerate Diagnostics' investor base is looking to short. The analysis of overall sentiment of trading Accelerate Diagnostics stock suggests that many investors are alarmed at this time. Accelerate Diagnostics' investing sentiment can be driven by a variety of factors including economic data, Accelerate Diagnostics' earnings reports, geopolitical events, and overall market trends.
  
Accelerate Diagnostics Scheduled Call to Review 2024 Third Quarter Results StockTitan

Read at news.google.com
Google News at Macroaxis
  

Accelerate Diagnostics Fundamental Analysis

We analyze Accelerate Diagnostics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Accelerate Diagnostics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Accelerate Diagnostics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Price To Sales

Price To Sales Comparative Analysis

Accelerate Diagnostics is currently under evaluation in price to sales category among its peers. Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.

Accelerate Diagnostics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Accelerate Diagnostics stock to make a market-neutral strategy. Peer analysis of Accelerate Diagnostics could also be used in its relative valuation, which is a method of valuing Accelerate Diagnostics by comparing valuation metrics with similar companies.

Peers

Accelerate Diagnostics Related Equities

NPCENeuropace   0.80   
0%
8.0%
SRDXSurModics   0.05   
0%
1.0%
ANIKAnika Therapeutics   0.11   
1.0%
0%
IRMDIradimed   0.44   
4.0%
0%
AORTArtivion   0.57   
6.0%
0%
ITGRInteger Holdings   0.87   
9.0%
0%
OFIXOrthofix Medical   0.91   
9.0%
0%
AXGNAxogen   1.08   
11.0%
0%
AVNSAvanos Medical   1.10   
11.0%
0%
LIVNLivaNova PLC   1.35   
14.0%
0%
SGHTSight Sciences   1.60   
17.0%
0%
CNMDCONMED   1.64   
17.0%
0%
KIDSOrthopediatrics Corp   5.29   
56.0%
0%
LUNGPulmonx Corp   5.67   
60.0%
0%
ELMDElectromed   6.04   
64.0%
0%
CVRXCVRx   9.40   
100.0%
0%

Additional Tools for Accelerate Stock Analysis

When running Accelerate Diagnostics' price analysis, check to measure Accelerate Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Accelerate Diagnostics is operating at the current time. Most of Accelerate Diagnostics' value examination focuses on studying past and present price action to predict the probability of Accelerate Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Accelerate Diagnostics' price. Additionally, you may evaluate how the addition of Accelerate Diagnostics to your portfolios can decrease your overall portfolio volatility.